Guest Editor: Prof. Kazuhiro Ito National Heart and Lung Institute, Imperial College, London, United Kingdom Email: k.ito@imperial.ac.uk  Website: https://profiles.imperial.ac.uk/k.ito

Guest Editor: Dr. Jonathan Baker National Heart and Lung Institute, Imperial College, London, United Kingdom Email: jonathan.r.baker@kcl.ac.uk Website: https://profiles.imperial.ac.uk/jonathan.baker/about

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality worldwide, with a disproportionate impact on aging populations. As life expectancy increases globally, the prevalence of COPD in older adults is projected to rise substantially, posing significant challenges to healthcare systems, caregivers, and patients alike. The interplay between age-related physiological changes and chronic airway inflammation/infection exacerbates disease progression, complicates diagnosis, and often limits therapeutic efficacy in this demographic.
This special issue brings together cutting-edge research, expert reviews, and clinical perspectives aimed at deepening our understanding of COPD within the context of aging. The collection focuses on key thematic areas:
•    Age-Related Pathophysiological Mechanisms: Contributions explore how immunosenescence, oxidative stress, mitochondrial dysfunction, cellular senescence, and all hallmarks of ageing influence COPD onset, progression, and heterogeneity in older adults.
•    Age-Related Biomarkers for Monitoring Disease Progression: Advanced imaging and biomarker profiling, and innovations in remote monitoring and digital health tools.
•    Pharmacological and Non-Pharmacological Interventions: This issue reviews evidence-based or novel therapies tailored to the elderly or targeting the aging process, including senolytic/senomorphic agents, anti-inflammatory strategies, oxygen therapy and nutritional support.

By assembling multidisciplinary perspectives, this collection seeks to advance precision medicine approaches in older individuals with COPD and promote actionable insights for clinicians, researchers, and policymakers. We hope it catalyzes innovation and collaboration toward improving outcomes and quality of life for this growing patient population.
 

Manuscript Submission Information

Manuscripts should be submitted online at www.antpublisher.com through the online submission system. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, Review articles as well as Therapeutic Brief are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. APT is an international peer-reviewed open access quarterly journal published by ANT.

Please visit the Instructions for Authors page before submitting a manuscript. Considering limited grants for some researchers, Dr. Sanjay Kalra, Dr. Nitin Kapoor and the editorial office made the decision that Article Processing Charges will be fully exempted, which means that there are NOT any manuscript processing or publication fees for your article once accepted after standard peer-review.

Submission Deadline

March 31th, 2026

Participants

Contacts

Updated on November 03, 2023